New Screening Test Will Focus on 4.3 Million Annual U.S. Birth Market
SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN) and Entest BioMedical Inc., BMSN's wholly-owned subsidiary, today announced that a contract has been signed with Dr. Brian Koos, a professor of Obstetrics and Gynecology at the David Geffen School of Medicine at
According to Dr. Koos, "There is a very large potential market for our screening test. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. Out of every 100 pregnant women in the U.S., three to eight get gestational diabetes. Diabetes means your blood glucose (or blood sugar) is too high. The body uses glucose for energy, but too much glucose in the blood can be harmful. An additional concern is that untreated or uncontrolled gestational diabetes can result in serious problems for your baby, such as being born very large and with extra fat. Such large infants are predisposed to birth injury and to obesity later in life. This non-invasive screening test for gestational diabetes, which is very reliable, is highly accurate in identifying women with gestational diabetes."
About Bio-Matrix Scientific Group Inc.:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.
About Entest BioMedical Inc.:
Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
|SOURCE Bio-Matrix Scientific Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved